

Robert Adalbert

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7555186/robert-adalbert-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

1,996
citations

20
h-index

33
g-index

33
ext. papers

2,309
ext. citations

7.3
avg, IF

4.13
L-index

#	Paper	IF	Citations
29	Imaging Axonal Transport in Ex Vivo Central and Peripheral Nerves.. <i>Methods in Molecular Biology</i> , 2022 , 2431, 73-93	1.4	1
28	Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1 mice. <i>Experimental Neurology</i> , 2021 , 338, 113607	5.7	9
27	Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors. <i>JCI Insight</i> , 2020 , 5,	9.9	25
26	Novel HDAC6 Inhibitors Increase Tubulin Acetylation and Rescue Axonal Transport of Mitochondria in a Model of Charcot-Marie-Tooth Type 2F. <i>ACS Chemical Neuroscience</i> , 2020 , 11, 258-267	5.7	9
25	Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport. <i>Neurobiology of Aging</i> , 2018 , 68, 68-75	5.6	13
24	TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. <i>Nature Neuroscience</i> , 2018 , 21, 552-563	25.5	111
23	Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016 , 26, 2920-2926	2.9	7
22	Axonal transport declines with age in two distinct phases separated by a period of relative stability. <i>Neurobiology of Aging</i> , 2015 , 36, 971-81	5.6	56
21	Age-related axonal swellings precede other neuropathological hallmarks in a knock-in mouse model of Huntington's disease. <i>Neurobiology of Aging</i> , 2014 , 35, 2382-93	5.6	16
20	Rescue of peripheral and CNS axon defects in mice lacking NMNAT2. <i>Journal of Neuroscience</i> , 2013 , 33, 13410-24	6.6	84
19	dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. <i>Science</i> , 2012 , 337, 481-4	33.3	403
18	Modelling early responses to neurodegenerative mutations in mice. <i>Biochemical Society Transactions</i> , 2011 , 39, 933-8	5.1	13
17	A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. <i>Neurochemistry International</i> , 2010 , 56, 937-47	4.4	112
16	Wld S protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice. <i>Journal of Cell Biology</i> , 2009 , 184, 491-500	7.3	93
15	Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. <i>Brain</i> , 2009 , 132, 402-16	11.2	119
14	Late onset distal axonal swelling in YFP-H transgenic mice. <i>Neurobiology of Aging</i> , 2009 , 30, 309-21	5.6	29
13	VCP binding influences intracellular distribution of the slow Wallerian degeneration protein, Wld(S). <i>Molecular and Cellular Neurosciences</i> , 2008 , 38, 325-40	4.8	14

12	Neuronal death: where does the end begin?. <i>Trends in Neurosciences</i> , 2007 , 30, 159-66	13.3	118
11	Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection. <i>Trends in Molecular Medicine</i> , 2007 , 13, 135-42	11.5	55
10	The slow Wallerian degeneration protein, WldS, binds directly to VCP/p97 and partially redistributes it within the nucleus. <i>Molecular Biology of the Cell</i> , 2006 , 17, 1075-84	3.5	51
9	The slow Wallerian degeneration gene in vivo protects motor axons but not their cell bodies after avulsion and neonatal axotomy. <i>European Journal of Neuroscience</i> , 2006 , 24, 2163-8	3.5	28
8	The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse. <i>Neurobiology of Disease</i> , 2005 , 19, 293-300	7.5	94
7	Neuroprotective strategies in MS: lessons from C57BL/Wld(S) mice. <i>Journal of the Neurological Sciences</i> , 2005 , 233, 133-8	3.2	21
6	The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. <i>Brain</i> , 2005 , 128, 405-16	11.2	95
5	A rat model of slow Wallerian degeneration (WldS) with improved preservation of neuromuscular synapses. <i>European Journal of Neuroscience</i> , 2005 , 21, 271-7	3.5	77
4	The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. <i>BMC Neuroscience</i> , 2005 , 6, 6	3.2	208
3	Quantitative and qualitative analysis of Wallerian degeneration using restricted axonal labelling in YFP-H mice. <i>Journal of Neuroscience Methods</i> , 2004 , 134, 23-35	3	91
2	DL-Homocysteic acid application disrupts calcium homeostasis and induces degeneration of spinal motor neurons in vivo. <i>Acta Neuropathologica</i> , 2002 , 103, 428-36	14.3	30
1	Calcium-containing endosomes at oculomotor terminals in animal models of ALS. <i>NeuroReport</i> , 1999 , 10, 2539-45	1.7	10